MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2024.1367514

Медицинская библиотека · Frontiers in immunology · 2024

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes.

Alleva David G, Delpero Andrea R, Sathiyaseelan Thillainaygam, Murikipudi Sylaja, Lancaster Thomas M, Atkinson Mark A, Wasserfall Clive H, Yu Liping, Ragupathy Ramya, Bonami Rachel H, Zion Todd C

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

INTRODUCTION

The antigen-presenting cell function of insulin-reactive B cells promotes type 1 diabetes (T1D) in non-obese diabetic (NOD) mice by stimulating pathogenic T cells leading to destruction of insulin-producing β-cells of pancreatic islets.

METHODS/

RESULTS

To target insulin-reactive B cells, AKS-107, a human IgG1 Fc molecule fused with human insulin A and B chains, was engineered to retain conformational insulin epitopes that bound mouse and human B cell receptors but prevented binding to the insulin metabolic receptor. AKS-107 Fc-mediated deletion of insulin-reactive B cells was demonstrated via ex vivo and in vivo experiments with insulin-reactive B cell receptor transgenic mouse strains, VH125Tg/NOD and Tg125(H+L)/NOD. As an additional immune tolerance feature, the Y16A mutation of the insulin B(9-23) dominant T cell epitope was engineered into AKS-107 to suppress activation of insulin-specific T cells. In mice and non-human primates, AKS-107 was well-tolerated, non-immunogenic, did not cause hypoglycemia even at high doses, and showed an expectedly protracted pharmacokinetic profile. AKS-107 reproducibly prevented spontaneous diabetes from developing in NOD and VH125Tg/NOD mice that persisted for months after cessation of treatment, demonstrating durable immune tolerance.

DISCUSSION: These preclinical outcomes position AKS-107 for clinical development in T1D prevention settings.

Для цитирования: Alleva David G, Delpero Andrea R, Sathiyaseelan Thillainaygam, Murikipudi Sylaja, Lancaster Thomas M, Atkinson Mark A, Wasserfall Clive H, Yu Liping, Ragupathy Ramya, Bonami Rachel H, Zion Todd C. An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes.. Frontiers in immunology. 2024. DOI: 10.3389/fimmu.2024.1367514.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.